Phase 4Not yet recruitingAge-related condition
Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary Syndrome (SEsiR-ACS)
Statin, Ezetimibe, and Inclisiran for Plaque Regression in Acute Coronary Syndrome: A Randomized Controlled Trial (SEsiR-ACS Trial)
- Sponsor
- Seoul National University Bundang Hospital (Academic or other)
- Enrollment
- 294 planned
- Conditions
- Acute Coronary Syndromes (ACS)
- Interventions
- Inclisiran; Atorvastatin or Rosuvastatin; Ezetimibe
- Ages
- adults, older adults
- Registry
- NCT07799779
Full record on ClinicalTrials.gov
From the registry
This multicenter, randomized, open-label clinical trial will evaluate whether an early intensive lipid-lowering strategy can improve coronary plaque stabilization in patients hospitalized with acute coronary syndrome. A total of 294 participants will be randomly assigned in a 1:1 ratio to either an early intensive treatment strategy with a high-intensity statin, ezetimibe, and inclisiran, or a guideline-based stepwise lipid-lowering strategy. Coronary plaque characteristics will be assessed using optical coherence tomography (OCT) at baseline and at 12 months. The primary outcome is the change in minimal fibrous cap thickness from baseline to 12 months. Additional assessments will include other OCT-based plaque characteristics, lipid levels, safety outcomes, and, in a subset of participants, intravascular ultrasound measurements of plaque burden.
Primary outcomes
- Change in Minimal Fibrous Cap Thickness
History
Primary completion expected
Expected to start
Last registry update
Registered